• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Infectious Disease

BNT162b2 booster is safe and reduces COVID-19 transmission in older adults

byNhat Hung (Benjamin) LamandKiera Liblik
January 30, 2023
in Infectious Disease, Public Health, Pulmonology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. The omicron BA.1-adapted BNT162b2 vaccine candidates elicited significant neutralizing antibodies against the omicron strains as well as the ancestral strains while maintaining similar safety to the original vaccine. 

2. The BA.1-adapted vaccine also induced neutralizing responses against the novel BA.4, BA.5, and BA.2.75 strains.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The coronavirus disease 2019 (COVID-19) pandemic is an ongoing public health issue. The BNT162b2 vaccine from Pfizer-BioNTech previously demonstrated effectiveness against previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and proved to be invaluable in the global strategy for combating COVID-19. However, the emergence of the highly transmissible omicron subvariants capable of evading immune responses prompted the need to adapt these vaccines and maintain adequate protection. The current study was an ongoing randomized trial to investigate the safety and efficacy of omicron BA.1-adapted BNT162b2 booster vaccine candidates for fully vaccinated adults older than 55 years. The BA.1-adapted vaccines elicited significant neutralizing antibodies against the omicron BA.1 strain while the bivalent vaccine also induced a response against the ancestral strain. The BA.1-adapted vaccines also induced limited neutralizing responses against other novel omicron BA.4, BA.5, and BA.2.75 subvariants. The main study limitation was its lack of longer-term follow-up amidst the rapidly evolving pandemic and emerging variants. Overall, among fully vaccinated older adults, the BA.1-adapted vaccines demonstrated sufficient safety and efficacy in inducing neutralizing antibody responses against the BA.1 omicron variant and, to a lesser degree, other novel omicron subvariants.

Click here to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: A Bivalent Omicron-Containing Booster Vaccine against Covid-19

RELATED REPORTS

101-PGC-005 improved hospitalized patients with COVID-19 faster than systemic dexamethasone in topline phase 2/3 results

Chronic exposure to particulate matter is associated with increased cardiovascular risk

FDA approvedFor COVID-19: Xocova (ensitrelvir), May 29, 2026→

In-Depth [randomized controlled trial]: The ongoing phase three randomized trial assessing the efficacy and safety of BA.1-adapted BNT162b2 booster vaccines for adults older than 55 years who had been fully vaccinated with three 30µg BNT162b2 doses. Overall, 1,846 participants were randomized 1:1:1:1:1:1 to receive 30µg or 60µg of BNT162b2, 30µg or 60µg of monovalent BA.1-adapted BNT162b2 (monovalent BA.1), or 30µg of (15µg of BNT162b2 + 15µg of monovalent BA.1) or 60µg (30µg of BNT162b2 + 30µg of monovalent BA.1) of BA.1-adapted BNT162b2 (bivalent BA.1). The primary objectives were to demonstrate superiority (based on the 50% neutralizing titers against SARS-CoV-2 [NT50]) and noninferiority of the immune response against omicron BA.1 elicited by the monovalent BA.1 or bivalent BA.1 booster compare to BNT162b2 given as a 4th dose. At one month following vaccination, both bivalent BA.1 (30µg and 60µg) and monovalent BA.1 (60µg) showed superior neutralizing activity against BA.1 compared to BNT162b2 (30µg), yielding NT50 geometric mean ratios (GMRs) of 1.56 (95% Confidence Interval [CI], 1.17 to 2.08), 1.97 (95% CI, 1.45 to 2.68), and 3.15 (95% CI, 2.38 to 4.16), respectively. With regards to protection against the ancestral strain, bivalent BA.1 (both doses) was noninferior to BNT162b2 (30µg), yielding NT50 GMRs of 0.99 (95% CI, 0.82 to 1.20) and 1.30 (95% CI, 1.07 to 1.58), respectively. As an exploratory analysis, neutralizing activity against the novel distinct omicron BA.4, BA.5, and BA.2.75 subvariants were also assessed. The 30µg bivalent BA.1 showed higher neutralizing titers against these subvariants than 30µg BNT162b2. Lastly, both BA.1-adapted vaccines had similar safety profiles to BNT162b2 with injection-site pain and fatigue being the most common adverse events, and no life-threatening reactogenicity was observed. These findings demonstrated that BA.1-adapted boosters had an acceptable safety profile and efficacy against ancestral and omicron BA.1 strains.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BA.1-adaptedBA.2.75BA.4BA.5bnt162b2BNT162b2 vaccineCOVID-19geriatricsinfectious diseaseomicronomicron BA.1-adapted BNT162b2 vaccinepublic healthpulmonology
Previous Post

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

Next Post

Online cooking education may improve perceived cooking and motor competencies in children

RelatedReports

A balance scale weighing an antiviral medication against a hospital entrance and a patient, symbolizing the outcomes of COVID-19 treatment.
2MM Trial Briefs

101-PGC-005 improved hospitalized patients with COVID-19 faster than systemic dexamethasone in topline phase 2/3 results

November 10, 2026
A senior woman looks thoughtfully at a balance scale with a stethoscope and a heart illustration, symbolizing the assessment of cardiovascular risk and treatment decisions.
Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Emergency

Lower levels of education and place of birth were associated with non-admission to the intensive care unit in Sweden during COVID-19 pandemic

September 1, 2026
Homelessness and health collage: a park bench with a bedroll and backpack, a path to a building with one lit window
Public Health

Mortality in the post-housing period is high among homeless people in Ottawa, Canada

August 31, 2026
Next Post

Online cooking education may improve perceived cooking and motor competencies in children

Teen smartphone use collage: a teenage boy in a hoodie looking down at a phone, with empty speech bubbles rising from it

Habitual social media use may alter neurodevelopment in adolescents

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
  • Interim global phase 2 AZUR-1 results show durable responses with dostarlimab monotherapy in untreated MSI-H/dMMR stage II/III locally advanced rectal cancer
  • AI health chatbot shows no benefit for perinatal anxiety or depression
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.